Solazyme, Inc. (NASDAQ: SZYM), a renewable oil and bioproducts company, announced today the successful commissioning of its first fully integrated biorefinery (IBR) in Peoria, Illinois, to produce algal oil. Solazyme has been running routine fermentations at commercial scale since 2007 and began running fermentation operations at the Peoria facility in Q4 2011. With the successful production of algal oil from the integrated facility this month, Solazyme has met its start-up goals for the facility on schedule. The IBR was partially funded with a federal grant that Solazyme received from the U.S. Department of Energy (DOE) in December 2009 to demonstrate integrated commercial-scale production of renewable algal-based fuels. The demonstration/ commercial-scale plant will have a nameplate capacity of two million liters of oil annually and will provide an important platform for continued work on feedstock flexibility and scaling of new tailored oils into the marketplace.
To maximize capital efficiency, Solazyme bought the existing Peoria fermentation facility in May 2011 and began retrofitting the former PMP Fermentation Products plant into an integrated demonstration/commercial-scale facility that will produce renewable tailored triglyceride. Solazyme has been operating at semi-commercial scale through contract manufacturers since 2007. The company has seen linear productivity in its scale-up efforts, including multiple toll manufacturing facilities and multiple successful 128,000-liter scale fermentations at Peoria.
"Bringing the Peoria IBR online is a major milestone for Solazyme and our ability to provide a new source of renewable oils that are specifically tailored to offer enhanced alternatives to conventional sources of oil. The Department of Energy has proven to be a valuable partner in demonstrating how important new technologies like Solazyme can positively impact this country’s economy, long-term job creation and energy independence efforts,” said Rogerio Manso, Chief Commercialization Officer.
About Solazyme, Inc.
Solazyme, Inc. (NASDAQ: SZYM) is a renewable oil and bioproducts company that transforms a range of low-cost plant-based sugars into high-value oils. Headquartered in South San Francisco, Solazyme’s renewable products can replace or enhance oils derived from the world’s three existing sources – petroleum, plants and animal fats. Initially, Solazyme is focused on commercializing its products into three target markets: (1) fuels and chemicals, (2) nutrition and (3) skin and personal care.
Solazyme®, the Solazyme logo and other trademarks or service names are trademarks of Solazyme, Inc.
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about Solazyme, including statements that involve risks and uncertainties concerning: the future production capacity at the Peoria facility; the products to be produced at the facility; the productivity that will be achieved at the facility; the attributes of Solazyme’s tailored oils; and the ability of Solazyme’s technologies to positively impact the economy, long-term job creation efforts and energy independence. When used in this press release, the words “will”, “expects”, “intends” and other similar expressions and any other statements that are not historical facts are intended to identify those assertions as forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any such statement may be influenced by a variety of factors, many of which are beyond the control of Solazyme, that could cause actual outcomes and results to be materially different from those projected, described, expressed or implied in this press release due to a number of risks and uncertainties. Potential risks and uncertainties include, among others: Solazyme’s limited operating history; risks associated with the development and scale-up of new technologies; its ability to enter into and maintain strategic collaborations; its ability to obtain requisite regulatory approvals; and its access, on favorable terms, to any required financing. Accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of Solazyme.
In addition, please refer to the documents that Solazyme files with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q, for a discussion of these and other risks. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this press release. Solazyme is not under any duty to update any of the information in this press release.